Al-Najami Issam, Drue Henrik C, Steele Robert, Baatrup Gunnar
Department of Surgery, Odense University Hospital, Svendborg, Denmark.
Department of Clinical Research, University of Southern Denmark, Denmark.
J Surg Oncol. 2017 Dec;116(8):984-988. doi: 10.1002/jso.24761. Epub 2017 Jul 13.
The measurement of tumor regression after neoadjuvant oncological treatment has gained increasing interest because it has a prognostic value and because it may influence the method of treatment in rectal cancer. The assessment of tumor regression remains difficult and inaccurate with existing methods. Dual Energy Computed Tomography (DECT) enables qualitative tissue differentiation by simultaneous scanning with different levels of energy. We aimed to assess the feasibility of DECT in quantifying tumor response to neoadjuvant therapy in loco-advanced rectal cancer.
We enrolled 11 patients with histological and MRI verified loco-advanced rectal adenocarcinoma and followed up on them prospectively. All patients had one DECT scanning before neoadjuvant treatment and one 12 weeks after using the spectral imaging scan mode. DECT analyzing tools were used to determine the average quantitative parameters; effective-Z, water- and iodine-concentration, Dual Energy Index (DEI), and Dual Energy Ratio (DER). These parameters were compared to the regression in the resection specimen as measured by the pathologist.
Changes in the quantitative parameters differed significantly after treatment in comparison with pre-treatment, and the results were different in patients with different CRT response rates.
DECT might be helpful in the assessment of rectal cancer regression grade after neoadjuvant treatment.
新辅助肿瘤治疗后肿瘤消退的测量越来越受到关注,因为它具有预后价值,且可能影响直肠癌的治疗方法。现有的方法对肿瘤消退的评估仍然困难且不准确。双能计算机断层扫描(DECT)通过不同能量水平的同时扫描实现组织的定性区分。我们旨在评估DECT在量化局部进展期直肠癌新辅助治疗的肿瘤反应方面的可行性。
我们纳入了11例经组织学和MRI证实的局部进展期直肠腺癌患者,并对其进行前瞻性随访。所有患者在新辅助治疗前进行一次DECT扫描,在使用光谱成像扫描模式12周后进行一次扫描。使用DECT分析工具确定平均定量参数;有效-Z、水和碘浓度、双能指数(DEI)和双能比(DER)。将这些参数与病理学家测量的切除标本中的消退情况进行比较。
与治疗前相比,治疗后定量参数的变化有显著差异,不同CRT反应率的患者结果也不同。
DECT可能有助于评估新辅助治疗后直肠癌的消退分级。